Anomalous warning labels on alcoholic energy drink cans
Authors: Genevieve A Cowie and Bruce Bolam
Published online: 17 November 2014
To the Editor: Despite longstanding calls for mandatory evidence-based warning labels on alcoholic beverages or at point of sale,1 they remain elusive and are actively resisted by industry groups.2
There is widespread ignorance of the current Australian guidelines to reduce health risks from drinking alcohol3 as well as the recommended daily limits for consuming highly caffeinated energy drinks. In high enough quantities, caffeine is toxic; consequently, some advisory labelling is already mandated for these controversial “soft” drinks.4 These labels are often difficult to find, and if the caffeine is from guarana only, a statement that the drink contains caffeine is the only warning required. This has resulted in anomalous and confusing labelling on cans of the even more contentious alcoholic energy drinks5 — such that consumers could be forgiven for thinking the alcohol component is not as potentially injurious to their health as the caffeine.
Based on caffeine content, labelling on cans that also contain between 1.3 and 1.9 standard drinks of alcohol advises a limit of two cans per day, which equates to a daily intake of between 2.6 and 3.8 standard drinks of alcohol. This exceeds the limit recommended in the Australian guidelines — two standard drinks per day — for reducing the risk of long-term damage to the body from alcohol.3 The advice on brands at the higher end of this range barely complies with the recommended limit of four standard drinks per day for preventing acute harm.
With such confusing advice, the general public cannot be expected to understand or follow recommended limits for either alcohol or caffeine consumption. Packaging should display unambiguous and prominent warnings, including whichever is the lower of the two daily use limits calculated according to guidelines on alcohol and caffeine intake. A second maximum might be given for usage in a single session. Public health messaging needs to be clear and consistent, and an overhaul of both alcohol and caffeine advisory labelling is long overdue.
Competing interests
No relevant disclosures.
Acknowledgements
Research giving rise to this letter was conducted as part of Genevieve Cowie's postgraduate placement with the Victorian Health Promotion Foundation, with workplace supervision by Bruce Bolam. The views expressed are our own, and responsibility rests solely with us. VicHealth did not review or endorse the contents of this letter. Genevieve Cowie receives a doctoral scholarship from the Department of Health, Victoria.
References
- Public Health Association of Australia Alcohol Special Interest Group. Public Health Association of Australia policy-at-a-glance – alcohol policy. PHAA, 2013. http://www.phaa.net.au/documents/130919 PHAA Alcohol Policy.pdf (accessed Sep 2014).
- Australian Hotels Association. Australian hotels: contributing to economic growth and national prosperity. A pre-election policy platform by the Australian Hotels Association (AHA) and Tourism Accommodation Australia (TAA). AHA and TAA, 2013. http://aha.org.au/wp-content/uploads/2013/07/AHA-National-Policy-Platform-2013.pdf (accessed Sep 2014).
- National Health and Medical Research Council. Australian guidelines to reduce health risks from drinking alcohol. Canberra: NHMRC, 2009. http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ds10-alcohol.pdf (accessed Oct 2014).
- Food Regulation Standing Committee Caffeine Working Group. Food regulation policy options paper: the regulation of caffeine in foods. Canberra: FRSC, 2013. http://www.health.gov.au/internet/main/publishing.nsf/Content/foodsecretariat-consult-previous (accessed Sep 2014).
- Trapp GS, Allen KL, O'Sullivan T, et al. Energy drink consumption among young Australian adults: associations with alcohol and illicit drug use. Drug Alcohol Depend 2014; 134: 30-37. _ENREF_5
Hospital-Admitted Injection-Related Infections Among Incarcerated People Who Inject Drugs in Australia: A Retrospective Cohort Study
Andrew Palmer, Matthew Carter, Jeremy Yeo, Cecilia Shim, Jason Connor, Jeremy Hayllar, Gerald Holtmann, Naomi Moy, Elliott G. Playford, Naomi Runnegar, Paul J. Clark
The Management of Withdrawal From Alcohol and Other Drugs in Australian Custodial Settings: A Consensus Statement
Grace FitzGerald, Jocelyn Chan, Jon Cook, Mark Stoove, Michael Curtis, Suzanne Nielsen, Rebecca J. Winter, Thileepan Naren
Impact of Prescription Drug Monitoring Program Implementation on Rates and Characteristics of People Seeing Multiple Prescribers in Primary Care: A Controlled Interrupted Time-Series Analysis
Louisa Picco, Monica Jung, Grant Russell, Samanta Lalic, Mahbod A. Fini, Dan I. Lubman, Rachelle Buchbinder, Ting Xia, Suzanne Nielsen
Early Cessation of Acetylcysteine Treatment After Paracetamol Overdose (NACSTOP 2): A Non-Inferiority Randomised Controlled Trial
Anselm Wong, Richard McNulty, Sarah E. Hodgson, Naren Gunja, Andis Graudins
The risk of death after hospitalisation following intentional self‐poisoning: a retrospective observational study (PAVLOVA‐2)
Firouzeh Noghrehchi, Nicholas A Buckley, Rose Cairns
Opioids and the challenges of managing chronic non‐cancer pain in rural Australia: a qualitative study
Jessica A Thomas, Jill Benson, Philip Davidson, Paul R Ward